Premium
Gene therapy of B‐cell lymphoma with cytokine gene‐modified trioma cells
Author(s) -
Strehl John,
Selmayr Michael,
Kremer JeanP.,
Hültner Lothar,
Lindhofer Horst,
Mocikat Ralph
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990924)83:1<113::aid-ijc20>3.0.co;2-j
Subject(s) - idiotype , lymphoma , cytokine , b cell lymphoma , cancer research , immunology , antibody , immunotherapy , b cell , genetic enhancement , vaccination , antigen , biology , immune system , medicine , gene , monoclonal antibody , genetics
The trioma approach is a new immunotherapeutic strategy for treating B‐cell lymphomas. It is based on converting the tumour idiotype to a bispecific immunoglobulin that redirects the idiotype to antigen‐presenting cells. We show here that even pre‐existing tumours can be eradicated by trioma vaccination, that the trioma approach is superior to vaccination with cytokine gene‐modified autologous tumour cells and that there is a synergism between trioma immunisation and GM‐CSF gene transfer. Furthermore, we show that the immunising potential of GM‐CSF gene‐modified autologous lymphoma cells is not as dependent on the cytokine expression level as described for other tumour models, such that even minute expression rates are effective. IL‐4 gene transfer in the lymphoma model is considerably less efficient or even ineffective when more sensitive systems are used. Remarkably, trioma‐mediated effects are extinguished when IL‐4 is expressed by the trioma cell. Int. J. Cancer 83:113–120, 1999. © 1999 Wiley‐Liss, Inc.